Treating Blood Cancers The Leukemia & Lymphoma Society

Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY

























Recorded on December 19, 2022







Lee Greenberger, PhD

Chief Scientific Officer and SVP

The Leukemia & Lymphoma Society

Rye Brook, NY





In this episode, Lee Greenberger, PhD, Chief Scientific Officer and Senior Vice President at The Leukemia & Lymphoma Society, returns to provide an update on the information presented at the 64th American Society of Hematology (ASH) Annual Meeting, including leukemia, lymphoma, myeloma, MDS, and MPNs. Dr. Greenberger discusses updates in blood cancer therapies, including CAR T-cell therapy, bi-specific antibodies, and vaccine therapy, reviews the latest data on COVID-19, and addresses challenges that exist in diversity and equity in the healthcare system, including ways to overcome these barriers. Tune in today!

Shayna Sarosiek, MD, Dana Farber Cancer Institute, Boston, MA

























Recorded on December 6, 2022







Shayna Sarosiek, MD

Assistant Professor

Harvard Medical School

Dana Farber Cancer Institute

Boston, MA





Waldenström Macroglobulinemia (WM) is a rare blood cell cancer characterized by an excess number of abnormal white blood cells in the bone marrow. How does WM fit into the spectrum of other blood cancer diseases? Who is at risk? What are the genetic factors? Dr. Shayna Sarosiek, from the Dana-Farber Cancer Institute, joins us to provide a deep dive into WM, including testing, monitoring, treatment updates, clinical trials, and so much more. Tune in today!











This activity is developed through a collaboration with the International Waldenström’s Macroglobulinemia Foundation.

Sattva S. Neelapu, MD, M.D. Anderson Cancer Center, Houston, TX

























Recorded on December 16, 2022







Sattva S. Neelapu, MD

Professor and Deputy Chair

Department of Lymphoma and Myeloma

The University of Texas M.D. Anderson Cancer Center

Houston, TX





Chimeric antigen receptor (CAR) T-cell therapy has generated impressive results in hematologic malignancies, with many drugs still in clinical trials. In this episode, Dr. Sattva S. Neelapu from MD Anderson Cancer Center, joins us to discuss updates on CAR T-cell therapy from the 2022 American Society of Hematology (ASH) Annual Meeting. Dr. Neelapu also provides a high-level overview of how CAR T-cell therapy works, including the manufacturing process, and discusses the risk of recurrence following therapy, risk for patients in the era of COVID-19, secondary cancers, associated costs, roadblocks to therapy, and why early referral matters. Tune in to this informative podcast episode to learn more!











This podcast episode is supported by Allogene Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Janssen Oncology & Legend Biotech, Kite, A Gilead Company and Novartis Oncology.

Daphne Friedman, MD, Durham VA Health Care System, Durham, NC

























Recorded on October 20, 2022







Daphne Friedman, MD

Staff Oncologist, Durham VA Health Care System

Associate Professor, Duke University School of Medicine

Durham, NC





In Part II of Shared Decision Making with Your Patients Diagnosed with a Chronic Leukemia, Dr. Daphne Friedman, from the Durham VA Health Care System in North Carolina, discusses the importance of a relationship between the provider and the patient when it comes to shared decision making (SDM), including the unique conversations of SDM with young adults and with healthcare providers who are patients. Dr. Friedman also shares challenges with seeking a second opinion, relying on information found on the internet, and additional resources. Tune in today to learn more!











This podcast episode is supported by AbbVie Inc. and Genentech, Inc.

Eytan M. Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY

























Recorded on October 7, 2022







Eytan M. Stein, MD

Chief, Leukemia Service

Director, Program for Drug Development in Leukemia

Associate Attending Physician

Leukemia Service, Department of Medicine

Memorial Sloan Kettering Cancer Center

New York, NY





Dr. Eytan Stein, from Memorial Sloan Kettering Cancer Center, joins us to reflect on breakthroughs in acute myeloid leukemia, including updates in treatment, long-term and late effects of therapy, and side effect management. Tune in to this episode as Dr. Stein discusses an overview of data presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) as well as updates from The Leukemia & Lymphoma Society’s BEAT AML® Master Trial.

Saad Z. Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY

























Recorded on September 30, 2022







Saad Z. Usmani, MD, MBA, FACP

Hematologic Oncologist

Chief, Myeloma Service

Memorial Sloan Kettering Cancer Center

New York, NY





Join us for this special episode, recorded live from the Tenth Annual Meeting of the Society of Hematologic Oncology in Houston, TX! Guest host and conference attendee, Lauren Berger, Senior Director of Professional Education and Engagement at The Leukemia & Lymphoma Society, speaks with Dr. Saad Usmani, from Memorial Sloan Kettering Cancer Center, about his insights into the progress in immunotherapies in blood cancers shared at the conference. Not able to attend SOHO? Learn more about what was shared at the conference by tuning in here!